drugset / Trial / NCT00439400

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

NCT00439400

Phase 2 Completed 160 enrolled Alacrity Biosciences, Inc.
RandomizedParallel-groupDouble-blind

Summary

The objective of this study is to assess the safety and efficacy of doxycycline 0.025% (ALTY-0501) ophthalmic solution for the treatment of dry eye using the Controlled Adverse Environment (CAE) Model.

Timeline

Start
2007-02
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxycycline Small molecule 0.025 % Topical

Indications